Lanvis

Lanvis

tioguanine

Manufacturer:

Aspen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Thioguanine
Indications/Uses
Acute myelogenous & lymphoblastic leukaemia.
Dosage/Direction for Use
Induction therapy 60-200 mg/m2 daily.
Administration
Should be taken on an empty stomach.
Contraindications
Special Precautions
Not recommended for maintenance therapy or similar long-term continuous therapy due to high risk of hepatic toxicity w/ vascular endothelial damage. Bone marrow suppression leading to leucopoenia, thrombocytopenia. Patients w/ inherited deficiency of thiopurine methyltransferase enzyme & NUDT15 gene variant; Lesch-Nyhan syndrome. Asian patients. Monitor full blood cell counts & hepatic function tests wkly. Limit exposure to sun- & UV light. Not recommended w/ live vaccines. Avoid use during pregnancy & lactation.
Adverse Reactions
Bone marrow failure; venoocclusive hepatic disease: hyperbilirubinaemia, hepatomegaly; increased wt, hepatic enzyme, blood alkaline phosphatase & γ-glutamyl-transferase; portal HTN & fibrosis; splenomegaly, varices oesophageal, thrombocytopenia, jaundice, nodular regenerative hyperplasia, peliosis hepatitis. Stomatitis, GI disorder; hyperuricaemia, hyperuricosuria, urate nephropathy.
Drug Interactions
Not recommended w/ live vaccines. Risk of myelosuppression w/ other myelotoxic substances or radiation therapy. Aminosalicylate derivatives eg, olsalazine, meslazine or sulphasalazine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BB03 - tioguanine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Lanvis tab 40 mg
Packing/Price
25's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in